No abstract available.
Amitriptyline/*therapeutic use ; Antidepressive Agents, Tricyclic/*therapeutic use ; Citalopram/*therapeutic use ; Dyspepsia/*drug therapy ; Female ; Humans ; Male ; *Quality of Life ; Serotonin Uptake Inhibitors/*therapeutic use

OBJECTIVETo investigate the clinical efficacy and reliability of citalopram in the treatment of premature ejaculation.

METHODSWe included in this study 80 patients who came to our andrological clinic for premature ejaculation from May 2011 to May 2012, and randomly assigned them to a treatment and a control group of equal number to receive citalopram (20 mg/d) and placebo, respectively. We recorded the intravaginal ejaculation latency time (IELT) and sexual intercourse satisfaction scores before and at 2 and 4 weeks after treatment, and compared them between the two groups.

RESULTSIn the treatment group, IELT was significantly longer at 2 and 4 weeks than before treatment ([5.64 +/- 1.31] and [7.12 +/- 1.56] min vs [0.91 +/- 0.18] min, P < 0.01), so was it at 4 than at 2 weeks (P < 0.01), and the sexual intercourse satisfaction scores were remarkably higher at 2 and 4 weeks than before treatment (6.1 +/- 1.3 and 6.3 +/- 1.1 vs 2.5 +/- 0.8, P < 0.01), but with no significant difference between 2 and 4 weeks (P > 0.05). The control group showed no significant differences in the mean IELT and sexual intercourse satisfaction scores between pre- and posttreatment ([1.01 +/- 0.21] vs [0.95 +/- 0.17 min; 3.1 +/- 1.3 vs 3.0 +/- 1.1, P > 0.05).

CONCLUSIONOral medication of citalopram at 20 mg/d can significantly prolong IELT and improve sexual intercourse satisfaction in patients with premature ejaculation.

Adult ; Citalopram ; therapeutic use ; Coitus ; Humans ; Male ; Middle Aged ; Patient Satisfaction ; Premature Ejaculation ; drug therapy ; Treatment Outcome ; Young Adult

OBJECTIVETo assess the early therapeutic and cognitive effect of repetitive transcranial magnetic stimulation (rTMS) combined with antidepressant medication in treatment of first-episode patients with major depression.

METHODSSixty first-episode depressed inpatients aged 18-45 y, who met the DSM-IV clinical criteria for major depressive episode were randomly assigned to citalopram treatment (20 mg/d) in combination with a two-week period of either rTMS (study group)or sham procedure (control group) on left dorsal-lateral prefrontal cortex (10 Hz, 90% motor threshold). The Hamilton Depression Rating Scale (HAMD) was used to assess the severity of depression. The Wisconsin Card Sorting Test (WCST) and Continuous Performance Test (CPT) were used to assess cognitive function of depression.

RESULTThe response rate was significantly greater in the study group compared to the control group after treatment (57% compared with 29%,P<0.05). The HAMD scores significantly declined after treatment in two groups, and the study group showed lower scores compared to the control group after 2 weeks (P<0.01). Neuropsychological assessments showed that there was no significant difference between the two groups except for the significant improvement in the categories on WCST in study group compared to the baseline (P<0.05) and the control group (P<0.05)after 2 weeks treatment. No serious event occurred in the patients during the rTMS study.

CONCLUSION10 Hz rTMS enhances early effects of citalopram and improves cognitive function in first-episode major depressive patients.

Adolescent ; Adult ; Antidepressive Agents ; therapeutic use ; Citalopram ; therapeutic use ; Combined Modality Therapy ; Depressive Disorder, Major ; therapy ; Humans ; Middle Aged ; Transcranial Magnetic Stimulation ; Treatment Outcome ; Young Adult

The patient was a 44-yr-old man with end-stage renal disease who had developed chorea as a result of hypoglycemic injury to the basal ganglia and thalamus and who was subsequently diagnosed with depression and restless legs syndrome (RLS). For proper management, the presence of a complex medical condition including two contrasting diseases, chorea and RLS, had to be considered. Tramadol improved the pain and dysesthetic restlessness in his feet and legs, and this was gradually followed by improvements in his depressed mood, insomnia, lethargy, and feelings of hopelessness. This case suggests that the dopaminergic system participates intricately with the opioid, serotoninergic, and noradrenergic systems in the pathophysiology of RLS and pain and indirectly of depression and insomnia.
Adult ; Analgesics, Opioid/therapeutic use ; Anti-Dyskinesia Agents/therapeutic use ; Chorea/*complications/pathology ; Citalopram/therapeutic use ; Drug Therapy, Combination ; Haloperidol/therapeutic use ; Humans ; Kidney Failure, Chronic/*complications ; Magnetic Resonance Imaging ; Male ; Restless Legs Syndrome/*complications/drug therapy/pathology ; Serotonin Uptake Inhibitors/therapeutic use ; Tramadol/therapeutic use

OBJECTIVETo evaluate the risk factors of psychiatric adverse events associated with PEG interferon and ribavirin treatment for chronic hepatitis C and assess the efficacy of escitalopram intervention for these adverse effects.

METHODSFifty-nine patients with chronic hepatitis C undergoing interferon-based treatment for 12 weeks were assessed for major depression using DSM-IV and SCL-90, and the patients identified to have major depression received escitalopram treatment for intervention. SCL-90 was used to assess the psychological condition of the patients at the forth and eighth weeks of escitalopram treatment.

RESULTSA male gender, 1b genotype, and intravenous infection are all risk factors of major depression. The morbidity rate of interferon-based depression was 32.2% with rates of hostility, anxiety, depression and sensitivity of 19.7%, 9.2%, and 5.26%, respectively. The total score of SCL-90 and scores for hostility, anxiety, depression and sensitivity all significantly declined after escitalopram treatment in the 19 patients with major depression.

CONCLUSIONSPsychological symptoms are common in HCV patients receiving interferon treatment, for whom regular psychological assessment is essential especially for those patients with drug abuse. Prompt use of escitalopram is recommended for effective control of major depression or other psychological symptoms in these patients.

Adult ; Antidepressive Agents, Second-Generation ; therapeutic use ; Antiviral Agents ; adverse effects ; therapeutic use ; Citalopram ; therapeutic use ; Depression ; chemically induced ; drug therapy ; Female ; Hepatitis C, Chronic ; drug therapy ; psychology ; Humans ; Interferon-alpha ; adverse effects ; therapeutic use ; Male ; Middle Aged ; Polyethylene Glycols ; adverse effects ; therapeutic use ; Recombinant Proteins ; adverse effects ; therapeutic use ; Risk Factors ; Treatment Outcome ; Young Adult